— Know what they know.
Not Investment Advice

ALBIO.PA PAR

Biosynex S.A.
1W: -3.4% 1M: +1.8% 3M: +0.9% YTD: -13.7% 1Y: -23.9% 3Y: -89.9% 5Y: -93.9%
€0.84 ($0.94)
-0.06 (-6.90%)
 
Weekly Expected Move ±7.4%
€1 €1 €1 €1 €1
PAR · Healthcare · Medical - Diagnostics & Research · Tech Score Sell · Power 43 · €16.6M mcap · 8M float · 0.237% daily turnover
Smart Money Score
No convergence signal
Key Statistics
Market Cap€16.6M ($18.5M)
52W Range0.455-1.57
Volume23,765
Avg Volume18,414
Beta0.83
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOLarry Abensur
Employees397
SectorHealthcare
IndustryMedical - Diagnostics & Research
IPO Date2011-03-28
22 Boulevard Sébastien Brant
Illkirch-Graffenstaden, GE 67400
FR
33 3 88 78 78 87
About Biosynex S.A.

Biosynex S.A. specializes in the development, manufacture, and worldwide distribution of rapid diagnostic solutions. Their extensive product line includes a variety of quick diagnostic assays, immunoblots, molecular biology tools, and point-of-care devices. These offerings are vital for screening, diagnosis, and prevention across numerous medical fields, such as bacteriology, parasitology, mycology, virology, biochemistry, oncology, and women's health, alongside specific COVID-19 tests and related instruments. Additionally, Biosynex provides consumer products like self-testing kits, personal health monitoring equipment (including thermometers and blood pressure monitors), and a selection of oral care and medical aid supplies. The company serves a diverse client base, including biological and medical analysis laboratories, hospitals, pharmacies, and large retail outlets like hypermarkets and supermarkets. Founded in 1993, Biosynex S.A. is headquartered in Illkirch-Graffenstaden, France.

Latest News
No recent news

Recent Insider Trades

No insider trades found

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms